News and Trends 28 Jul 2022 Commercial launch of Monkeypox PCR test announced for research A PCR test to pick up the monkeypox virus is now available outside the US for use in research applications by laboratories. Becton, Dickinson and Company (BD) a global medical technology company and CerTesy Biotec made the announcement today (July 27). The BD MAX System used to leverage the test is a fully integrated, automated […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […] July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Opinion 25 Jul 2022 How to improve patient recruitment in your precision medicine research Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […] July 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Stroke drug given priority medicine status by European Medicines Agency A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 BigHat Biosciences raises $75M to design safer, more effective antibodies A company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today (July 20) announced it has raised $75 million in funding. BigHat Biosciences’ series B funding round was led by Section 32 with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital and others. […] July 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Good news for Destiny Pharma’s nasal gel to combat life-threatening infections Clinical stage biotech company, Destiny Pharma, announced today (July 19) a positive update from the U.S. Food and Drug Administration (FDA) on its XF-73 nasal gel phase 3 development plans. The FDA has clarified the phase 3 and U.S. registration pathway for the gel for the prevention of post-surgical staphylococcal infections, and this feedback enables […] July 19, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 Oncoshot raises cash to speed up clinical trial enrolment with AI The Singapore-based startup Oncoshot has raised an undisclosed amount in a pre-Series A round to drive the expansion of its artificial intelligence (AI)-driven clinical trial enrolment technology into Australia and India. The round, led by the tech-focused venture capital firm MassMutual Ventures, allows Oncoshot to pursue its mission of eliminating barriers to the recruitment of […] July 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Orthox green light for knee cartilage repair clinical trial Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, can start its FFLEX (FibroFix cartilage repair experience) study. The company has received a Letter of No Objection from the UK’s MHRA, enabling the start of the study. The study, which is also supported by funding […] July 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab Drug development is a lengthy and costly process that takes at least 10 years on average from drug discovery to commercialization, requiring billions of dollars in investment. However, over 90% of new drugs that are tested in clinical trials fail. Organoids — three-dimensional, patient-derived mini-organs in a dish — offer a solution to this challenge. […] July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email